Comparing the Effect of Botulinum Toxin Type B Injection at Different Dosages for Patient with Drooling due to Brain Lesion
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective To investigate Botulinum toxin type B (BNT-B) injection’s effect and duration depending on dose for patients with brain lesion.Method Twenty one patients with brain lesion and severe drooling were included and divided into three groups. All patients received conventional dysphagia therapy. Group A patients (n=7) received an injection of 1,500 units and group B patients (n=7) received an injection of 2,500 units of BNT-B in submandibular gland under ultrasound guidance. Group C patients (n=7) received conventional dysphagia therapy. Saliva secretion was assessed quantitatively at baseline and at weeks 1, 2, 4, 8, and 12. The severity and frequency of drooling was assessed using the Drooling Quotient (DQ) by patients and/or caregivers.Results Group A and B reported a distinct improvement of the symptoms within 2 weeks after BNT-B injection. Compared to the baseline, the mean amount of saliva decreased significantly throughout the study. However, there was no meaningful difference between the two groups. The greatest reductions were achieved at 2 weeks and lasted up to 8 weeks after BNT-B injection. Group C did not show any differences.Conclusion Local injection of 1,500 units of BNT-B into salivary glands under ultrasonic guidance proved to be a safe and effective dose for drooling in patient with brain lesion, as did 2,500 units.
Abstract
Objective To investigate Botulinum toxin type B (BNT-B) injection’s effect and duration depending on dose for patients with brain lesion.Method Twenty one patients with brain lesion and severe drooling were included and divided into three groups. All patients received conventional dysphagia therapy. Group A patients (n=7) received an injection of 1,500 units and group B patients (n=7) received an injection of 2,500 units of BNT-B in submandibular gland under ultrasound guidance. Group C patients (n=7) received conventional dysphagia therapy. Saliva secretion was assessed quantitatively at baseline and at weeks 1, 2, 4, 8, and 12. The severity and frequency of drooling was assessed using the Drooling Quotient (DQ) by patients and/or caregivers.Results Group A and B reported a distinct improvement of the symptoms within 2 weeks after BNT-B injection. Compared to the baseline, the mean amount of saliva decreased significantly throughout the study. However, there was no meaningful difference between the two groups. The greatest reductions were achieved at 2 weeks and lasted up to 8 weeks after BNT-B injection. Group C did not show any differences.Conclusion Local injection of 1,500 units of BNT-B into salivary glands under ultrasonic guidance proved to be a safe and effective dose for drooling in patient with brain lesion, as did 2,500 units.
참고문헌 (20)
- Hockstein NG, "Sialorrhea: a management challenge", Am Fam Physician, 69, pp.2628~2634 (2004)
- Hussein I, "The management of drooling in children and patient with mental and physical disablities: a literature review", Int J Pediartr Dent, 8, pp.3~11 (1998)
- Proulx M, "Salivary production in Parkinson’s disease", Mov Disord, 20, pp.204~207 (2005)
- Giess R, "Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis", J Neurol Neurosurg Psychiatry, 69, pp.121~123 (2000)
- Suskind DL, "Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy", Laryngoscope, 112, pp.73~81 (2002)
- Banerjee KJ, "Parotid and submandibular botulinum toxin A injections for sialorrhoea in children with cerebral palsy", Dev Med Child Neurol, 48, pp.883~887 (2006)
- Mankarious LA, "Long-term follow-up of submandibular duct rerouting for the treatment of sialorrhea in the pediatric population", Otolaryngol Head Neck Surg, 120, pp.303~307 (1999)
- Brin MF, "Safery and efficacy of NeuroBlock (botulinum toxin type B) in type A-resistant cervical dystonia", Neurology, 53, pp.1431~1438 (1999)
- Bushara KO, "Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment - botulinum toxin A injections of the parotid glands", Med Hypotheses, 48, pp.337~339 (1997)
- Lagalla G, "Long-lasting benefits of botulinum toxin type B in Parkinson’s disease-related drooling", J Neurol, 256, pp.563~567 (2009)
- Ondo WG, "A double-blind placebo- controlled trial of botulium toxin B for sialorrhea in Parkinson’s diease", Neurology, 62, pp.37~40 (2004)
- Enfors BO, "The parotid and submandibular secretion in man. Quantitative recordings of the normal and pathological activity", Acta Otolaryngol Suppl, 172, pp.1~67 (1962)
- Jongerius PH, "The treatment of posterior drooling by botulinum toxin in a child with cerebral palsy", J Pediatr Gastroenterol Nutr, 41, pp.351~353 (2005)
- Banerjee KJ, "Parotid and submandibular botulinum toxin A injections for sialorrhoea in children with cerebral palsy", Dev Med Child Neurol, 48, pp.883~887 (2006)
- Freed ML, "Christian M. Electrical stimulation for swallowing disorders caused by stroke", Respir Care, 46, pp.466~474 (2001)
- Kim H, "Botulinum toxin type A injection to salivary glands: combination with single event multilevel chemoineirolysis in 2 children with severe spastic qudriplegic cerebral palsy", Arch Phys Med Rehabil, 87, pp.141~144 (2006)
- Blasco PA, "Drooling in the developmentally disabled: management practices and recommendations. Consortium on drooling", Dev Med Child Neurol, 34, pp.849~862 (1992)
- 배하석, "성인 외상성 뇌손상 환자에서 침 흘림 증상에 영향을 미치는 인자", Annals of Rehabilitation Medicine, 30(5), pp.424~429 (2006), 대한재활의학회
- Jongerius PH, "The treatment of drooling by ultrasoundquided intraglandular injections of botulinum toxin type A into the salivary glands", Laryngoscope, 113, pp.107~111 (2003)
- Dressler D, "Botulinum toxin type B for treatment of axillar hyperhidrosis", J neurol, 249, pp.1729~1732 (2002)